Executive summary Prostate cancer is the most common cancer in men in 112 countries,
and accounts for 15% of cancers. In this Commission, we report projections of prostate …

The non-coding RNAs comprise a large part of human genome lack of capacity in encoding
functional proteins. Among various members of non-coding RNAs, the circular RNAs …

Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Background Abiraterone acetate plus prednisolone improves survival in men with relapsed
prostate cancer. We assessed the effect of this combination in men starting long-term …

Simple Summary Prostate cancer is the most common tumor in men. Although there have
been many new developments in the last few years, metastatic castration resistant prostate …

Background Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus
prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the …

Prostate cancer (PCa) is the most common worldwide diagnosed malignancy in male
population. The diagnosis, the identification of aggressive disease, and the post-treatment …

Background Long-term hormone therapy has been the standard of care for advanced
prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a …

Background Androgen-deprivation therapy (ADT) has been the backbone of treatment for
metastatic prostate cancer since the 1940s. We assessed whether concomitant treatment …